Amanda Feilding: Psychedelic Researcher
Amanda Feilding is a British countess, artist, and scientific researcher who has dedicated her life to studying the effects of psychedelic chemicals. She is the founder of the Beckley Foundation, a nonprofit organization that conducts research on psychoactive substances with the goal of determining their potential benefits and detriments. Feilding is known for her groundbreaking work on the therapeutic potential of psilocybin, the active ingredient in magic mushrooms. Her research has helped pave the way for the legal and medicinal use of psychedelics in the modern age. In this blog post, we’ll delve into the incredible life and work of Amanda Feilding, exploring her journey with magic mushrooms, as well as her research on the potential benefits of psychedelic chemicals.
Feilding’s love for psychoactive substances began in her youth when she first tried marijuana while attending boarding school. This sparked her fascination with altered states of consciousness, and she soon began experimenting with other substances like LSD, mescaline, and magic mushrooms. In the 1960s, Feilding traveled to the Amazon Rainforest in search of the ayahuasca plant, which is used in traditional shamanic practices for its hallucinogenic properties. Her experiences with these substances led her to believe that they had the potential to transform human consciousness and improve mental health.
Feilding’s research on psychedelics began in the early 2000s when she founded the Beckley Foundation. The organization’s first major project involved studying the effects of psilocybin on brain function and mood. In this study, participants were given psilocybin in a controlled environment and then underwent brain scans to measure changes in neural activity. The results showed that psilocybin increased connectivity between brain regions, leading to a more integrated and cohesive sense of self. Feilding and her team also found that psilocybin had therapeutic potential for conditions like depression, anxiety, and addiction.
Feilding has also conducted research on other psychoactive substances like LSD, ibogaine, and DMT. In 2019, the Beckley Foundation launched a study on the effects of LSD microdosing, which involves taking small, regular doses of the drug to improve cognitive function and creativity. The study is the first of its kind and could have major implications for how we treat mental health conditions.
In addition to her scientific research on psychoactive substances, Feilding is also an advocate for drug policy reform. She believes that the prohibition of drugs like marijuana and psychedelics is flawed and that these substances should be regulated and used for medicinal purposes. Feilding has worked with politicians and policymakers around the world to change drug laws and promote more rational drug policy.
Amanda Feilding is a trailblazer in the world of psychedelic research, whose work has pushed the boundaries of what we know about these powerful substances. Her studies on psilocybin and other psychoactive chemicals have provided valuable insights into their therapeutic potential and could lead to new treatments for mental health conditions. Feilding’s advocacy for drug policy reform is also important, as it highlights the need for a more rational and evidence-based approach to drug regulation. As we continue to learn more about the potential benefits of psychedelics, it’s clear that Feilding’s pioneering work will have a lasting impact on both the scientific community and society at large.
Leave a Reply